New affordable hepatitis C combination shows 97% cure rate
New South Wales puts 9000 people on PrEP, achieves a one-third decline in new HIV infections
PrEP use growing in US, but not reaching all those in need
HIV prevention: It’s time to stop accepting the status quo, PrEP Summit concludes
What are the barriers to HIV testing and treatment access – and how do we overcome them?
The availability of direct-acting antivirals is reducing disparities in the uptake of hepatitis C treatment
Trans women wary of antiretroviral drug and hormone interactions
Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows
Hepatitis C treatment is effective and feasible in Africa
